ES2108642B1 - Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus. - Google Patents

Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.

Info

Publication number
ES2108642B1
ES2108642B1 ES9501603A ES9501603A ES2108642B1 ES 2108642 B1 ES2108642 B1 ES 2108642B1 ES 9501603 A ES9501603 A ES 9501603A ES 9501603 A ES9501603 A ES 9501603A ES 2108642 B1 ES2108642 B1 ES 2108642B1
Authority
ES
Spain
Prior art keywords
tungsten
compositions
pharmaceutical compositions
diabetes mellitus
oral treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES9501603A
Other languages
English (en)
Spanish (es)
Other versions
ES2108642A1 (es
Inventor
Cirera Joan Josep Guinovart
Lluis Albert Barbera
Gil Joan Enric Rodriguez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Hispania SL
Original Assignee
Quimica Farmaceutica Bayer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US08/504,020 priority Critical patent/US5595763A/en
Application filed by Quimica Farmaceutica Bayer SA filed Critical Quimica Farmaceutica Bayer SA
Priority to ES9501603A priority patent/ES2108642B1/es
Priority to EP96500106A priority patent/EP0755681A1/en
Priority to JP19733096A priority patent/JPH09118624A/ja
Publication of ES2108642A1 publication Critical patent/ES2108642A1/es
Application granted granted Critical
Publication of ES2108642B1 publication Critical patent/ES2108642B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES9501603A 1995-07-19 1995-07-26 Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus. Expired - Fee Related ES2108642B1 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US08/504,020 US5595763A (en) 1995-07-19 1995-07-19 Tungsten (VI) compositions for the oral treatment of diabetes mellitus
ES9501603A ES2108642B1 (es) 1995-07-26 1995-07-26 Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.
EP96500106A EP0755681A1 (en) 1995-07-19 1996-07-25 Tungsten (VI) compositions for the oral treatment of diabetes mellitus
JP19733096A JPH09118624A (ja) 1995-07-26 1996-07-26 真性糖尿病の経口処置用タングステン（ｖｉ）組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9501603A ES2108642B1 (es) 1995-07-26 1995-07-26 Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.

Publications (2)

Publication Number Publication Date
ES2108642A1 ES2108642A1 (es) 1997-12-16
ES2108642B1 true ES2108642B1 (es) 1998-08-16

Family

ID=8291317

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9501603A Expired - Fee Related ES2108642B1 (es) 1995-07-19 1995-07-26 Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.

Country Status (2)

Country Link
JP (1) JPH09118624A (https=)
ES (1) ES2108642B1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2187276B1 (es) * 2001-05-16 2004-08-01 Quimica Farmaceutica Bayer,S.A. Composiciones orales para el tratamiento de humanos obesos y no diabeticos.
EP1972342A4 (en) * 2005-07-29 2011-01-12 Univ Barcelona PHARMACEUTICAL TREATED SALT (VI) COMPOSITIONS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDERS, IN PARTICULAR ALZHEIMER DISEASE AND SCHIZOPHRENIA
CN100515428C (zh) * 2007-04-26 2009-07-22 暨南大学 钨酸锂在制药中的应用
ES2478696B1 (es) * 2012-12-21 2015-05-06 Universitat De Barcelona Sales de tungstato como agentes antiplaquetarios
ES2478790B1 (es) 2013-01-22 2015-05-06 Oxolife, S. L. Uso de sales de tungsteno (VI) para el tratamiento de la infertilidad femenina en mamíferos no diabéticos
ES2551828B1 (es) * 2014-05-21 2016-09-12 Oxolife S.L. Composiciones alimentarias que comprenden sales de tungsteno (VI)
CA2955914C (en) 2014-07-21 2022-09-06 Ignacio Canals Almazan Tungsten (vi) salts for use thereof in the treatment of infertility, for favoring normal reproduction and fertility in a non-diabetic female mammal, as well as for improving the efficacy of assisted reproductive techniques

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6025916A (ja) * 1983-07-21 1985-02-08 Tanaka Seinosuke 入浴水
JPS6025928A (ja) * 1983-07-21 1985-02-08 Tanaka Seinosuke 薬剤

Also Published As

Publication number Publication date
JPH09118624A (ja) 1997-05-06
ES2108642A1 (es) 1997-12-16

Similar Documents

Publication Publication Date Title
BR0015295A (pt) Formulação e método antidiabético
DE69928006T2 (de) Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1
PT693924E (pt) Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
NZ217483A (en) Composition for delivery of hydrophobic drugs
TR200001891T2 (tr) ASPB28- İnsan ensülini ve kullanımı.
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
CR6458A (es) Composiciones de valdecoxib
DE19975040I2 (de) Medikamente enthaltend Salmeterol und Fluticason
BRPI0207700B8 (pt) mistura de conjugados monodispersa, composição farmacêutica, e, uso de uma mistura substancialmente monodispersa de um conjugado de polipeptídeo de insulina-oligômero
ES2089027T3 (es) Forma de dosificacion transmucosica.
RU94022479A (ru) Применение антиэстрогенных соединений, а также фармацевтически приемлемых солей и сольватов для уменьшения концентрации глюкозы в крови, фармацевтический препарат
ATE191719T1 (de) Analoge des calcitonin aus lachs, ihre herstellung und ihre verwendung als medizin und als analytische reagentien
ATE92762T1 (de) Medikamente.
ES2119748T3 (es) Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
ES2108642B1 (es) Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.
SE8602743D0 (sv) Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
KR950703353A (ko) 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus)
US6589995B2 (en) Method of inhibiting pancreatic β-cell p135 O-glycosylation
ATE13488T1 (de) Gallium-chlorid, ein neues antikrebsmittel.
BR0111464A (pt) Composição farmacêutica na forma de dosagem unitária, e, método de tratamento de um paciente com nefropatia diabética
Anderson et al. Acute Toxicity of Trypan Blue, Gentian Violet and Brilliant Green.
RU2033152C1 (ru) Средство для стимуляции гемопоэза
DE60120371D1 (de) Verwendung von wachstumshormon in niederen dosen

Legal Events

Date Code Title Description
PC2A Transfer granted

Owner name: QUIMICA FARMACEUTICA BAYER, S.A.

FD1A Patent lapsed

Effective date: 20100528